| Year |
Citation |
Score |
| 2020 |
Vala C, Mothes C, Chicheri G, Magadur P, Viot G, Deloye JB, Maia S, Bouvet Y, Dupont AC, Arlicot N, Guilloteau D, Emond P, Vercouillie J. Fully automated radiosynthesis of [F]LBT999 on TRACERlab FX and AllinOne modules, a PET radiopharmaceutical for imaging the dopamine transporter in human brain. Ejnmmi Radiopharmacy and Chemistry. 5: 26. PMID 33196944 DOI: 10.1186/s41181-020-00105-w |
0.679 |
|
| 2020 |
Ribeiro MJ, Vercouillie J, Arlicot N, Tauber C, Gissot V, Mondon K, Barantin L, Cottier JP, Maia S, Deloye JB, Emond P, Guilloteau D. Usefulness of PET With [F]LBT-999 for the Evaluation of Presynaptic Dopaminergic Neuronal Loss in a Clinical Environment. Frontiers in Neurology. 11: 754. PMID 32973645 DOI: 10.3389/fneur.2020.00754 |
0.68 |
|
| 2020 |
Ribeiro M, Vercouillie J, Arlicot N, Tauber C, Gissot V, Mondon K, Barantin L, Cottier J, Maia S, Deloye J, Emond P, Guilloteau D. Usefulness of PET With [18F]LBT-999 for the Evaluation of Presynaptic Dopaminergic Neuronal Loss in a Clinical Environment Frontiers in Neurology. 11. DOI: 10.3389/Fneur.2020.00754 |
0.704 |
|
| 2019 |
Arlicot N, Vercouillie J, Malherbe C, Bidault R, Gissot V, Maia S, Barantin L, Cottier JP, Deloye JB, Guilloteau D, Ribeiro MJ. PET imaging of Dopamine Transporter with [18F]LBT-999: initial evaluation in healthy volunteers. The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (Aimn) [and] the International Association of Radiopharmacology (Iar), [and] Section of the Society of.... PMID 31496203 DOI: 10.23736/S1824-4785.19.03175-3 |
0.694 |
|
| 2019 |
Chalon S, Vercouillie J, Payoux P, Deloye JB, Malherbe C, Le Jeune F, Arlicot N, Salabert AS, Guilloteau D, Emond P, Ribeiro MJ. The Story of the Dopamine Transporter PET Tracer LBT-999: From Conception to Clinical Use. Frontiers in Medicine. 6: 90. PMID 31131278 DOI: 10.3389/Fmed.2019.00090 |
0.699 |
|
| 2019 |
Elie J, Vercouillie J, Arlicot N, Lemaire L, Bidault R, Bodard S, Hosselet C, Deloye JB, Chalon S, Emond P, Guilloteau D, Buron F, Routier S. Design of selective COX-2 inhibitors in the (aza)indazole series. Chemistry, in vitro studies, radiochemistry and evaluations in rats of a [F] PET tracer. Journal of Enzyme Inhibition and Medicinal Chemistry. 34: 1-7. PMID 30362376 DOI: 10.1080/14756366.2018.1501043 |
0.656 |
|
| 2019 |
Malherbe C, Bidault R, Netter C, Guilloteau D, Vercouillie J, Arlicot N. Development of a Fast and Facile Analytical Approach to Quantify Radiometabolites in Human Plasma Samples Using Ultra High Performance Liquid Chromatography American Journal of Analytical Chemistry. 10: 185-201. DOI: 10.4236/Ajac.2019.105016 |
0.659 |
|
| 2018 |
Dupont AC, Largeau B, Guilloteau D, Santiago Ribeiro MJ, Arlicot N. The Place of PET to Assess New Therapeutic Effectiveness in Neurodegenerative Diseases. Contrast Media & Molecular Imaging. 2018: 7043578. PMID 29887768 DOI: 10.1155/2018/7043578 |
0.686 |
|
| 2018 |
Beaufils E, Vercouillie J, Vierron E, Cottier JP, Camus V, Mondon K, Guilloteau D, Hommet C, Ribeiro MJ. Amyloid PET Positivity in Different Primary Progressive Aphasia Phenotypes. Clinical Nuclear Medicine. 43: e103-e108. PMID 29504965 DOI: 10.1097/Rlu.0000000000002018 |
0.304 |
|
| 2018 |
Ribeiro MS, Vercouillie J, Gissot V, Maia S, Barantin L, Peltier Y, Cottier J, Deloye J, Arlicot N, Guilloteau D. Le 18F-LBT-999, le nouveau traceur TEP du DAT ? MéDecine NucléAire. 42: 137-138. DOI: 10.1016/J.Mednuc.2018.03.017 |
0.616 |
|
| 2017 |
Largeau B, Dupont AC, Guilloteau D, Santiago-Ribeiro MJ, Arlicot N. TSPO PET Imaging: From Microglial Activation to Peripheral Sterile Inflammatory Diseases? Contrast Media & Molecular Imaging. 2017: 6592139. PMID 29114179 DOI: 10.1155/2017/6592139 |
0.681 |
|
| 2017 |
Tronel C, Largeau B, Santiago Ribeiro MJ, Guilloteau D, Dupont AC, Arlicot N. Molecular Targets for PET Imaging of Activated Microglia: The Current Situation and Future Expectations. International Journal of Molecular Sciences. 18. PMID 28398245 DOI: 10.3390/Ijms18040802 |
0.659 |
|
| 2017 |
Dupont AC, Largeau B, Santiago Ribeiro MJ, Guilloteau D, Tronel C, Arlicot N. Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases. International Journal of Molecular Sciences. 18. PMID 28387722 DOI: 10.3390/Ijms18040785 |
0.693 |
|
| 2017 |
Genne P, Berthet C, Raguin O, Chalon S, Tizon X, Serriere S, Provent P, Boisferon MHd, Vercouillie J, Mothes C, Gourand F, Barre L, Guilloteau D, Blom P, Hoflack J. Abstract 1875A: Preclinical proof of concept for the first Nanocyclix TKI-PET radiotracer targeting activated EGFR positive lung tumors Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-1875A |
0.303 |
|
| 2017 |
Santiago Ribeiro M, Vercouillie J, Maia S, Gissot V, Bonnet Brilhault F, Guilloteau D, Arlicot N. Cinétique cérébrale du [18F]-FPEB, radioligand spécifique du mGluR5, chez le volontaire sain MéDecine NucléAire. 41: 168-169. DOI: 10.1016/J.Mednuc.2017.02.080 |
0.635 |
|
| 2016 |
Barbet J, Arlicot N, Gaugler MH, Chérel M, Guilloteau D, Kraeber-Bodéré F. Editorial: Innovative Radiopharmaceuticals in Oncology and Neurology. Frontiers in Medicine. 3: 74. PMID 28123998 DOI: 10.3389/Fmed.2016.00074 |
0.64 |
|
| 2016 |
Zimmer L, Breton P, Durand G, Guilloteau D, Besnard JC, Chalon S. Prominent Role of n-3 Polyunsaturated Fatty Acids in Cortical Dopamine Metabolism. Nutritional Neuroscience. 2: 257-65. PMID 27415577 DOI: 10.1080/1028415X.1999.11747282 |
0.347 |
|
| 2016 |
Dupont AC, Guilloteau D, Kassiou M, Ribeiro MJ, Vercouillie J, Katsifis A, Arlicot N. Radiopharmaceuticals for PET imaging of neuroinflammation Medecine Nucleaire. 40: 72-81. DOI: 10.1016/J.Mednuc.2016.01.001 |
0.679 |
|
| 2015 |
Bailly M, Ribeiro MJ, Vercouillie J, Hommet C, Gissot V, Camus V, Guilloteau D. 18F-FDG and 18F-florbetapir PET in clinical practice: regional analysis in mild cognitive impairment and Alzheimer disease. Clinical Nuclear Medicine. 40: e111-6. PMID 25549345 DOI: 10.1097/Rlu.0000000000000666 |
0.321 |
|
| 2015 |
Dupont A, Guilloteau D, Ben-Azzouna R, Bidault R, Algalarrondo V, Slama M, Arlicot N, Le Guludec D. [18F]FDDNP performed better than [18F] Florbetapir to distinguish transthyretin cardiac amyloidosis (TTR-CA) patients from healthy controls: an ex vivo study Orphanet Journal of Rare Diseases. 10. DOI: 10.1186/1750-1172-10-S1-P38 |
0.645 |
|
| 2014 |
Arlicot N, Tronel C, Bodard S, Garreau L, de la Crompe B, Vandevelde I, Guilloteau D, Antier D, Chalon S. Translocator Protein (18 kDa) Mapping with [(125)I]-CLINDE in the Quinolinic Acid Rat Model of Excitotoxicity: A Longitudinal Comparison with Microglial Activation, Astrogliosis, and Neuronal Death. Molecular Imaging. 13: 7290201300075. PMID 28650286 DOI: 10.2310/7290.2013.00075 |
0.646 |
|
| 2014 |
Ribeiro MJ, Vercouillie J, Debiais S, Cottier JP, Bonnaud I, Camus V, Banister S, Kassiou M, Arlicot N, Guilloteau D. Could (18) F-DPA-714 PET imaging be interesting to use in the early post-stroke period? Ejnmmi Research. 4: 28. PMID 25006546 DOI: 10.1186/S13550-014-0028-4 |
0.664 |
|
| 2014 |
Arlicot N, Tronel C, Bodard S, Garreau L, de la Crompe B, Vandevelde I, Guilloteau D, Antier D, Chalon S. Translocator protein (18 kDa) mapping with [125I]-CLINDE in the quinolinic acid rat model of excitotoxicity: a longitudinal comparison with microglial activation, astrogliosis, and neuronal death. Molecular Imaging. 13: 4-11. PMID 24622813 DOI: 10.2310/7290.2013.00075 |
0.673 |
|
| 2014 |
Sérrière S, Tauber C, Vercouillie J, Guilloteau D, Deloye JB, Garreau L, Galineau L, Chalon S. In vivo PET quantification of the dopamine transporter in rat brain with [¹⁸F]LBT-999. Nuclear Medicine and Biology. 41: 106-13. PMID 24210285 DOI: 10.1016/J.Nucmedbio.2013.09.007 |
0.43 |
|
| 2014 |
Hommet C, Mondon K, Camus V, Ribeiro MJ, Beaufils E, Arlicot N, Corcia P, Paccalin M, Minier F, Gosselin T, Page G, Guilloteau D, Chalon S. Neuroinflammation and β amyloid deposition in Alzheimer's disease: in vivo quantification with molecular imaging. Dementia and Geriatric Cognitive Disorders. 37: 1-18. PMID 24107621 DOI: 10.1159/000354363 |
0.655 |
|
| 2013 |
Martins AF, Morfin JF, Kubí?ková A, Kubí?ek V, Buron F, Suzenet F, Salerno M, Lazar AN, Duyckaerts C, Arlicot N, Guilloteau D, Geraldes CF, Tóth E. PiB-Conjugated, Metal-Based Imaging Probes: Multimodal Approaches for the Visualization of β-Amyloid Plaques. Acs Medicinal Chemistry Letters. 4: 436-40. PMID 24900692 DOI: 10.1021/Ml400042W |
0.635 |
|
| 2013 |
Tauber C, Beaufils E, Hommet C, Ribeiro MJ, Vercouillie J, Vierron E, Mondon K, Cottier JP, Gissot V, Guilloteau D, Camus V. Brain [18F]FDDNP binding and glucose metabolism in advanced elderly healthy subjects and Alzheimer's disease patients. Journal of Alzheimer's Disease : Jad. 36: 311-20. PMID 23609763 DOI: 10.3233/Jad-122068 |
0.343 |
|
| 2013 |
Petitcollin A, Maia S, Guilloteau D, Dupuis S, Arlicot N. Développement d’une méthode rapide de chromatographie sur couche mince pour le contrôle qualité du 99mTc-HMPAO en routine MéDecine NucléAire. 37: 171. DOI: 10.1016/J.Mednuc.2013.03.137 |
0.597 |
|
| 2013 |
Santiago-Ribeiro M, Vercouillie J, Corcia P, Arlicot N, Erra B, Maia S, Bonnaud I, Debiais S, Kassiou M, Guilloteau D. Distribution cérébrale du 18F-DPA-714 et neuro-inflammation aiguë et chronique MéDecine NucléAire. 37: 141-142. DOI: 10.1016/J.Mednuc.2013.03.025 |
0.6 |
|
| 2013 |
Erra B, Vercouillie J, Corcia P, Maïa S, Arlicot N, Baulieu J, Guilloteau D, Santiago Ribeiro M. Distribution physiologique cérébrale et corps entier du 18F-DPA-714 en TEP/TDM MéDecine NucléAire. 37: 44-51. DOI: 10.1016/J.Mednuc.2013.01.004 |
0.646 |
|
| 2012 |
Corcia P, Tauber C, Vercoullie J, Arlicot N, Prunier C, Praline J, Nicolas G, Venel Y, Hommet C, Baulieu JL, Cottier JP, Roussel C, Kassiou M, Guilloteau D, Ribeiro MJ. Molecular imaging of microglial activation in amyotrophic lateral sclerosis. Plos One. 7: e52941. PMID 23300829 DOI: 10.1371/Journal.Pone.0052941 |
0.663 |
|
| 2012 |
La Joie R, Perrotin A, Barré L, Hommet C, Mézenge F, Ibazizene M, Camus V, Abbas A, Landeau B, Guilloteau D, de La Sayette V, Eustache F, Desgranges B, Chételat G. Region-specific hierarchy between atrophy, hypometabolism, and β-amyloid (Aβ) load in Alzheimer's disease dementia. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 32: 16265-73. PMID 23152610 DOI: 10.1523/Jneurosci.2170-12.2012 |
0.319 |
|
| 2012 |
Mazère J, Meissner WG, Mayo W, Sibon I, Lamare F, Guilloteau D, Tison F, Allard M. Progressive supranuclear palsy: in vivo SPECT imaging of presynaptic vesicular acetylcholine transporter with [123I]-iodobenzovesamicol. Radiology. 265: 537-43. PMID 23012462 DOI: 10.1148/Radiol.12112650 |
0.366 |
|
| 2012 |
Leaver KR, Reynolds A, Bodard S, Guilloteau D, Chalon S, Kassiou M. Effects of translocator protein (18 kDa) ligands on microglial activation and neuronal death in the quinolinic-acid-injected rat striatum. Acs Chemical Neuroscience. 3: 114-9. PMID 22860181 DOI: 10.1021/Cn200099E |
0.318 |
|
| 2012 |
Maia S, Arlicot N, Vierron E, Bodard S, Vergote J, Guilloteau D, Chalon S. Longitudinal and parallel monitoring of neuroinflammation and neurodegeneration in a 6-hydroxydopamine rat model of Parkinson's disease. Synapse (New York, N.Y.). 66: 573-83. PMID 22337286 DOI: 10.1002/Syn.21543 |
0.687 |
|
| 2012 |
Mavel S, Mincheva Z, Méheux N, Carcenac Y, Guilloteau D, Abarbri M, Emond P. QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT). Bioorganic & Medicinal Chemistry. 20: 1388-95. PMID 22300887 DOI: 10.1016/J.Bmc.2012.01.014 |
0.395 |
|
| 2012 |
Camus V, Payoux P, Barré L, Desgranges B, Voisin T, Tauber C, La Joie R, Tafani M, Hommet C, Chételat G, Mondon K, de La Sayette V, Cottier JP, Beaufils E, Ribeiro MJ, ... ... Guilloteau D, et al. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. European Journal of Nuclear Medicine and Molecular Imaging. 39: 621-31. PMID 22252372 DOI: 10.1007/S00259-011-2021-8 |
0.353 |
|
| 2012 |
Arlicot N, Vercouillie J, Ribeiro MJ, Tauber C, Venel Y, Baulieu JL, Maia S, Corcia P, Stabin MG, Reynolds A, Kassiou M, Guilloteau D. Initial evaluation in healthy humans of [18F]DPA-714, a potential PET biomarker for neuroinflammation. Nuclear Medicine and Biology. 39: 570-8. PMID 22172392 DOI: 10.1016/J.Nucmedbio.2011.10.012 |
0.692 |
|
| 2012 |
Santiago-Ribeiro M, Vercouille J, Tauber C, Venel Y, Baulieu J, Maia S, Arlicot N, Corcia P, Kassiou M, Guilloteau D. Cinétique cérébrale du [18F]DPA-714 en tomographie par émission de positons chez le volontaire sain MéDecine NucléAire. 36: 169. DOI: 10.1016/J.Mednuc.2012.02.039 |
0.656 |
|
| 2012 |
Duval S, Siñeriz F, Arlicot N, Barbier-Chassefire V, Vercouillie J, Delbé J, Papy-Garcia D, Guilloteau D, Barritault D. Development of radiotracers for the molecular imaging of tumor matrix microenvironment (HIMIMT) | Développement de radiotraceurs pour l'imagerie moléculaire du microenvironnement matriciel tumoral (HIMIMT) Irbm. 33: 86-91. DOI: 10.1016/J.Irbm.2012.01.006 |
0.626 |
|
| 2011 |
Varrone A, Stepanov V, Nakao R, Tóth M, Gulyás B, Emond P, Deloye JB, Vercouillie J, Stabin MG, Jonsson C, Guilloteau D, Halldin C. Imaging of the striatal and extrastriatal dopamine transporter with (18)F-LBT-999: quantification, biodistribution, and radiation dosimetry in nonhuman primates. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 52: 1313-21. PMID 21764797 DOI: 10.2967/Jnumed.111.089953 |
0.374 |
|
| 2011 |
Varrone A, Tóth M, Steiger C, Takano A, Guilloteau D, Ichise M, Gulyás B, Halldin C. Kinetic analysis and quantification of the dopamine transporter in the nonhuman primate brain with 11C-PE2I and 18F-FE-PE2I. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 52: 132-9. PMID 21189414 DOI: 10.2967/Jnumed.110.077651 |
0.309 |
|
| 2010 |
Arlicot N, Petit E, Katsifis A, Toutain J, Divoux D, Bodard S, Roussel S, Guilloteau D, Bernaudin M, Chalon S. Detection and quantification of remote microglial activation in rodent models of focal ischaemia using the TSPO radioligand CLINDE. European Journal of Nuclear Medicine and Molecular Imaging. 37: 2371-80. PMID 20814674 DOI: 10.1007/S00259-010-1598-7 |
0.618 |
|
| 2010 |
Giboureau N, Som IM, Boucher-Arnold A, Guilloteau D, Kassiou M. PET radioligands for the vesicular acetylcholine transporter (VAChT). Current Topics in Medicinal Chemistry. 10: 1569-83. PMID 20583990 DOI: 10.2174/156802610793176846 |
0.405 |
|
| 2010 |
Song PJ, Barc C, Arlicot N, Guilloteau D, Bernard S, Sarradin P, Chalon S, Garreau L, Kung HF, Lantier F, Vergote J. Evaluation of prion deposits and microglial activation in scrapie-infected mice using molecular imaging probes. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 12: 576-82. PMID 20376566 DOI: 10.1007/S11307-010-0321-1 |
0.656 |
|
| 2010 |
Varrone A, Tóth M, Steiger C, Takano A, Guilloteau D, Ichise M, Gulyás B, Halldin C. Kinetic analysis and quantification of the dopamine transporter in the non-human primate brain with [11C]PE2I and [18F]FE-PE2I Neuroimage. 52. DOI: 10.1016/J.Neuroimage.2010.04.137 |
0.36 |
|
| 2010 |
Varrone A, Tóth M, Stepanov V, Nakao R, Gulyás B, Emond P, Deloye JB, Vercouillie J, Halldin C, Guilloteau D. Quantification of [18F]LBT-999 binding to the dopamine transporter in the rhesus monkey brain with the HRRT system Neuroimage. 52: S118-S119. DOI: 10.1016/J.Neuroimage.2010.04.097 |
0.387 |
|
| 2010 |
Vercouillie J, Prenant C, Maia S, Emond P, Guillouet S, Deloye JB, Barré L, Guilloteau D. Automated production of [18F]FDDNP using a TRACERlab MXFDG Journal of Labelled Compounds and Radiopharmaceuticals. 53: 208-212. DOI: 10.1002/Jlcr.1745 |
0.317 |
|
| 2009 |
Schou M, Steiger C, Varrone A, Guilloteau D, Halldin C. Synthesis, radiolabeling and preliminary in vivo evaluation of [18F]FE-PE2I, a new probe for the dopamine transporter. Bioorganic & Medicinal Chemistry Letters. 19: 4843-5. PMID 19577467 DOI: 10.1016/J.Bmcl.2009.06.032 |
0.314 |
|
| 2008 |
Mavel S, Vercouillie J, Garreau L, Raguza T, Ravna AW, Chalon S, Guilloteau D, Emond P. Docking study, synthesis, and in vitro evaluation of fluoro-MADAM derivatives as SERT ligands for PET imaging. Bioorganic & Medicinal Chemistry. 16: 9050-5. PMID 18793858 DOI: 10.1016/J.Bmc.2008.08.002 |
0.399 |
|
| 2008 |
Arlicot N, Katsifis A, Garreau L, Mattner F, Vergote J, Duval S, Kousignian I, Bodard S, Guilloteau D, Chalon S. Evaluation of CLINDE as potent translocator protein (18 kDa) SPECT radiotracer reflecting the degree of neuroinflammation in a rat model of microglial activation. European Journal of Nuclear Medicine and Molecular Imaging. 35: 2203-11. PMID 18536913 DOI: 10.1007/S00259-008-0834-X |
0.769 |
|
| 2008 |
Emond P, Guilloteau D, Chalon S. PE2I: a radiopharmaceutical for in vivo exploration of the dopamine transporter. Cns Neuroscience & Therapeutics. 14: 47-64. PMID 18482099 DOI: 10.1111/j.1527-3458.2007.00033.x |
0.357 |
|
| 2008 |
James ML, Fulton RR, Vercoullie J, Henderson DJ, Garreau L, Chalon S, Dolle F, Costa B, Selleri S, Guilloteau D, Kassiou M. DPA-714, a new translocator protein-specific ligand: synthesis, radiofluorination, and pharmacologic characterization. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 49: 814-22. PMID 18413395 DOI: 10.2967/Jnumed.107.046151 |
0.318 |
|
| 2008 |
Bouchez G, Sensebé L, Vourc'h P, Garreau L, Bodard S, Rico A, Guilloteau D, Charbord P, Besnard JC, Chalon S. Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease. Neurochemistry International. 52: 1332-42. PMID 18372079 DOI: 10.1016/J.Neuint.2008.02.003 |
0.311 |
|
| 2008 |
Chitneni SK, Garreau L, Cleynhens B, Evens N, Bex M, Vermaelen P, Chalon S, Busson R, Guilloteau D, Van Laere K, Verbruggen A, Bormans G. Improved synthesis and metabolic stability analysis of the dopamine transporter ligand [(18)F]FECT. Nuclear Medicine and Biology. 35: 75-82. PMID 18158946 DOI: 10.1016/J.Nucmedbio.2007.09.001 |
0.412 |
|
| 2008 |
Arlicot N, Katsifis A, Garreau L, Mattner F, Vergote J, Duval S, Kousignian I, Bodard S, Guilloteau D, Chalon S. Evaluation of CLINDE as potent translocator protein (18 kDa) SPECT radiotracer reflecting the degree of neuroinflammation in a rat model of microglial activation (European Journal of Nuclear Medicine and Molecular Imaging DOI: 10.1007/s00259-008-0834-x) European Journal of Nuclear Medicine and Molecular Imaging. 35: 2341. DOI: 10.1007/s00259-008-0882-2 |
0.768 |
|
| 2007 |
Giboureau N, Emond P, Fulton RR, Henderson DJ, Chalon S, Garreau L, Roselt P, Eberl S, Mavel S, Bodard S, Fulham MJ, Guilloteau D, Kassiou M. Ex vivo and in vivo evaluation of (2R,3R)-5-[(18)F]-fluoroethoxy- and fluoropropoxy-benzovesamicol, as PET radioligands for the vesicular acetylcholine transporter. Synapse (New York, N.Y.). 61: 962-70. PMID 17787004 DOI: 10.1002/Syn.20450 |
0.403 |
|
| 2007 |
Vercouillie J, Deuther-Conrad W, Scheunemann M, Emond P, Fischer S, Funke U, Steinbach J, Guilloteau D, Brust P. New fluoro-diphenylchalcogen derivatives to explore the serotonin transporter by PET. Bioorganic & Medicinal Chemistry Letters. 17: 4991-5. PMID 17658253 DOI: 10.1016/J.Bmcl.2007.02.082 |
0.408 |
|
| 2007 |
Saba W, Valette H, Schöllhorn-Peyronneau MA, Coulon C, Ottaviani M, Chalon S, Dolle F, Emond P, Halldin C, Helfenbein J, Madelmont JC, Deloye JB, Guilloteau D, Bottlaender M. [11C]LBT-999: a suitable radioligand for investigation of extra-striatal dopamine transporter with PET. Synapse (New York, N.Y.). 61: 17-23. PMID 17068778 DOI: 10.1002/Syn.20337 |
0.802 |
|
| 2007 |
Assaad T, Mavel S, Emond P, Chalon S, Drossard ML, Vergote J, Bodard S, Allouchi H, Besnard J, Guilloteau D. Synthesis andex vivo evaluation of aza-trozamicol analogs as SPECT radiotracers for exploration of the vesicular acetylcholine transporter Journal of Labelled Compounds and Radiopharmaceuticals. 50: 139-145. DOI: 10.1002/Jlcr.1244 |
0.802 |
|
| 2006 |
Assaad T, Mavel S, Parsons SM, Kruse S, Galineau L, Allouchi H, Kassiou M, Chalon S, Guilloteau D, Emond P. Synthesis and in vitro evaluation of N-substituted aza-trozamicol analogs as vesicular acetylcholine transporter ligands. Bioorganic & Medicinal Chemistry Letters. 16: 2654-7. PMID 16516472 DOI: 10.1016/J.Bmcl.2006.02.033 |
0.786 |
|
| 2006 |
Chalon S, Hall H, Saba W, Garreau L, Dollé F, Halldin C, Emond P, Bottlaender M, Deloye JB, Helfenbein J, Madelmont JC, Bodard S, Mincheva Z, Besnard JC, Guilloteau D. Pharmacological characterization of (E)-N-(4-fluorobut-2-enyl)-2beta-carbomethoxy-3beta-(4'-tolyl)nortropane (LBT-999) as a highly promising fluorinated ligand for the dopamine transporter. The Journal of Pharmacology and Experimental Therapeutics. 317: 147-52. PMID 16339913 DOI: 10.1124/Jpet.105.096792 |
0.802 |
|
| 2006 |
Dollé F, Emond P, Mavel S, Demphel S, Hinnen F, Mincheva Z, Saba W, Valette H, Chalon S, Halldin C, Helfenbein J, Legaillard J, Madelmont JC, Deloye JB, Bottlaender M, ... Guilloteau D, et al. Synthesis, radiosynthesis and in vivo preliminary evaluation of [11C]LBT-999, a selective radioligand for the visualisation of the dopamine transporter with PET. Bioorganic & Medicinal Chemistry. 14: 1115-25. PMID 16219467 DOI: 10.1016/J.Bmc.2005.09.035 |
0.805 |
|
| 2006 |
Chalon S, Guilloteau D, Bodard S, Ferry S. Exploration of the monoaminergic neurotransmission: Localisation of several receptors and transporters in the Marmoset brain Toxicology Letters. 164: S118-S119. DOI: 10.1016/J.Toxlet.2006.06.249 |
0.315 |
|
| 2006 |
Saba W, Schöllhorn M-, Valette H, Chalon S, Dolle F, Garreau L, Emond P, Deloye JB, Guilloteau D, Bottlaender M. [18F]LBT-999, a new radioligand to study the dopamine transporter with PET: Characterization in baboons Neuroimage. 31. DOI: 10.1016/J.Neuroimage.2006.04.116 |
0.391 |
|
| 2005 |
Zea-Ponce Y, Mavel S, Assaad T, Kruse SE, Parsons SM, Emond P, Chalon S, Giboureau N, Kassiou M, Guilloteau D. Synthesis and in vitro evaluation of new benzovesamicol analogues as potential imaging probes for the vesicular acetylcholine transporter. Bioorganic & Medicinal Chemistry. 13: 745-53. PMID 15653342 DOI: 10.1016/J.Bmc.2004.10.043 |
0.76 |
|
| 2004 |
Chalon S, Bronquard C, Vercouillie J, Kodas E, Garreau L, Bodard S, Emond P, Besnard JC, Guilloteau D. ADAM is an effective tool for in vivo study of serotonergic function: validation in rat models. Synapse (New York, N.Y.). 52: 136-42. PMID 15034919 DOI: 10.1002/Syn.20012 |
0.357 |
|
| 2003 |
Meissner W, Prunier C, Guilloteau D, Chalon S, Gross CE, Bezard E. Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease. Molecular Neurobiology. 28: 209-18. PMID 14709785 DOI: 10.1385/Mn:28:3:209 |
0.362 |
|
| 2003 |
Prunier C, Bézard E, Montharu J, Mantzarides M, Besnard JC, Baulieu JL, Gross C, Guilloteau D, Chalon S. Presymptomatic diagnosis of experimental Parkinsonism with 123I-PE2I SPECT. Neuroimage. 19: 810-6. PMID 12880809 DOI: 10.1016/S1053-8119(03)00163-0 |
0.349 |
|
| 2003 |
Halldin C, Erixon-Lindroth N, Pauli S, Chou YH, Okubo Y, Karlsson P, Lundkvist C, Olsson H, Guilloteau D, Emond P, Farde L. [(11)C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain. European Journal of Nuclear Medicine and Molecular Imaging. 30: 1220-30. PMID 12811422 DOI: 10.1007/S00259-003-1212-3 |
0.305 |
|
| 2003 |
Bagot-Guéret C, Le Bas MD, Tymciu S, Darabantu M, Emond P, Guilloteau D, Lasne MC, Wijkhuisen A, Barré L, Perrio C. Synthesis and biological evaluation of halogenated naphthyridone carboxamides as potential ligands for in vivo imaging studies of substance P receptors. Bioconjugate Chemistry. 14: 629-41. PMID 12757389 DOI: 10.1021/Bc025656R |
0.301 |
|
| 2003 |
Fernagut PO, Chalon S, Diguet E, Guilloteau D, Tison F, Jaber M. Motor behaviour deficits and their histopathological and functional correlates in the nigrostriatal system of dopamine transporter knockout mice. Neuroscience. 116: 1123-30. PMID 12617953 DOI: 10.1016/S0306-4522(02)00778-9 |
0.328 |
|
| 2003 |
Chalon S, Tarkiainen J, Garreau L, Hall H, Emond P, Vercouillie J, Farde L, Dasse P, Varnas K, Besnard JC, Halldin C, Guilloteau D. Pharmacological characterization of N,N-dimethyl-2-(2-amino-4-methylphenyl thio)benzylamine as a ligand of the serotonin transporter with high affinity and selectivity. The Journal of Pharmacology and Experimental Therapeutics. 304: 81-7. PMID 12490578 DOI: 10.1124/Jpet.102.042226 |
0.395 |
|
| 2002 |
Kodas E, Vancassel S, Lejeune B, Guilloteau D, Chalon S. Reversibility of n-3 fatty acid deficiency-induced changes in dopaminergic neurotransmission in rats: critical role of developmental stage. Journal of Lipid Research. 43: 1209-19. PMID 12177165 DOI: 10.1194/Jlr.M200132-Jlr200 |
0.327 |
|
| 2002 |
Gouhier C, Chalon S, Aubert-Pouessel A, Venier-Julienne MC, Jollivet C, Benoit JP, Guilloteau D. Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease. Synapse (New York, N.Y.). 44: 124-31. PMID 11954043 DOI: 10.1002/Syn.10063 |
0.766 |
|
| 2002 |
Barc S, Page G, Barrier L, Garreau L, Guilloteau D, Fauconneau B, Chalon S. Relevance of different striatal markers in assessment of the MPP+-induced dopaminergic nigrostriatal injury in rat. Journal of Neurochemistry. 80: 365-74. PMID 11905985 DOI: 10.1046/J.0022-3042.2001.00743.X |
0.389 |
|
| 2002 |
Emond P, Vercouillie J, Innis R, Chalon S, Mavel S, Frangin Y, Halldin C, Besnard JC, Guilloteau D. Substituted diphenyl sulfides as selective serotonin transporter ligands: synthesis and in vitro evaluation. Journal of Medicinal Chemistry. 45: 1253-8. PMID 11881994 DOI: 10.1021/Jm010939A |
0.373 |
|
| 2002 |
Chalon S, Vancassel S, Zimmer L, Guilloteau D, Durand G. Polyunsaturated fatty acids and cerebral function: focus on monoaminergic neurotransmission. Lipids. 36: 937-44. PMID 11724466 DOI: 10.1007/S11745-001-0804-7 |
0.337 |
|
| 2002 |
Prunier C, Tranquart F, Cottier JP, Giraudeau B, Chalon S, Guilloteau D, De Toffol B, Chossat F, Autret A, Besnard JC, Baulieu JL. Quantitative analysis of striatal dopamine D2 receptors with 123 I-iodolisuride SPECT in degenerative extrapyramidal diseases. Nuclear Medicine Communications. 22: 1207-14. PMID 11606886 DOI: 10.1097/00006231-200111000-00007 |
0.338 |
|
| 2001 |
Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, Guilloteau D, Crossman AR, Bioulac B, Brotchie JM, Gross CE. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 21: 6853-61. PMID 11517273 DOI: 10.1523/Jneurosci.21-17-06853.2001 |
0.349 |
|
| 2001 |
Emond P, Helfenbein J, Chalon S, Garreau L, Vercouillie J, Frangin Y, Besnard JC, Guilloteau D. Synthesis of tropane and nortropane analogues with phenyl substitutions as serotonin transporter ligands. Bioorganic & Medicinal Chemistry. 9: 1849-55. PMID 11425587 DOI: 10.1016/S0968-0896(01)00083-9 |
0.772 |
|
| 2001 |
Diot P, Galinier E, Grimbert D, Bugeon S, Valat C, Lemarié E, Diot E, Baulieu JL, Besnard JC, Guilloteau D. Characterization of 99mTc-DTPA aerosols for lung permeability studies. Respiration; International Review of Thoracic Diseases. 68: 313-7. PMID 11416254 DOI: 10.1159/000050516 |
0.739 |
|
| 2001 |
Bezard E, Boraud T, Chalon S, Brotchie JM, Guilloteau D, Gross CE. Pallidal border cells: an anatomical and electrophysiological study in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey. Neuroscience. 103: 117-23. PMID 11311792 DOI: 10.1016/S0306-4522(00)00546-7 |
0.344 |
|
| 2001 |
Tranquart F, Saliba E, Barantin L, Lanneau M, Simmer L, Guilloteau D, Baulieu JL. D2 receptor imaging in neonates using I-123 iodobenzamide brain SPECT. Clinical Nuclear Medicine. 26: 36-40. PMID 11139051 DOI: 10.1097/00003072-200101000-00009 |
0.306 |
|
| 2000 |
Gouhier C, Chalon S, Venier-Julienne MC, Bodard S, Benoit J, Besnard J, Guilloteau D. Neuroprotection of nerve growth factor-loaded microspheres on the D2 dopaminergic receptor positive-striatal neurones in quinolinic acid-lesioned rats: a quantitative autoradiographic assessment with iodobenzamide. Neuroscience Letters. 288: 71-5. PMID 10869818 DOI: 10.1016/S0304-3940(00)01172-1 |
0.76 |
|
| 2000 |
Zimmer L, Delpal S, Guilloteau D, Aïoun J, Durand G, Chalon S. Chronic n-3 polyunsaturated fatty acid deficiency alters dopamine vesicle density in the rat frontal cortex. Neuroscience Letters. 284: 25-8. PMID 10771153 DOI: 10.1016/S0304-3940(00)00950-2 |
0.325 |
|
| 2000 |
Chalon S, Pellevoisin C, Bodard S, Vilar MP, Besnard JC, Guilloteau D. Iodinated PK 11195 as an ex vivo marker of neuronal injury in the lesioned rat brain. Synapse (New York, N.Y.). 24: 334-9. PMID 10638824 DOI: 10.1002/(Sici)1098-2396(199612)24:4<334::Aid-Syn3>3.0.Co;2-E |
0.37 |
|
| 2000 |
Dolle F, Bottlaender M, Demphel S, Emond P, Fuseau C, Coulon C, Ottaviani M, Valette H, Loc'h C, Halldin C, Mauclaire L, Guilloteau D, Maziere B, Crouzel C. Highly efficient synthesis of [11C]PE2I, a selective radioligand for the quantification of the dopamine transporter using PET Journal of Labelled Compounds and Radiopharmaceuticals. 43: 997-1004. DOI: 10.1002/1099-1344(200009)43:10<997::Aid-Jlcr385>3.0.Co;2-# |
0.425 |
|
| 2000 |
Sandell J, Halldin C, Helfenbein J, Chou Y, Vercouillie J, Emond P, Swahn C, Guilloteau D, Farde L. Synthesis of [11C]2?-carbomethoxy-3?-(3?-iodo-4?-methyl, -ethyl and isopropyl phenyl)nortropane as potential radiotracers for examination of the serotonin transporter with positron emission tomography Journal of Labelled Compounds and Radiopharmaceuticals. 43: 1033-1046. DOI: 10.1002/1099-1344(200009)43:10<1033::Aid-Jlcr389>3.0.Co;2-5 |
0.789 |
|
| 1999 |
Helfenbein J, Loc'h C, Bottlaender M, Emond P, Coulon C, Ottaviani M, Fuseau C, Chalon S, Guenther I, Besnard JC, Frangin Y, Guilloteau D, Maziere B. A selective radiobrominated cocaine analogue for imaging of dopamine uptake sites: pharmacological evaluation and PET experiments. Life Sciences. 65: 2715-26. PMID 10622281 DOI: 10.1016/S0024-3205(99)00540-8 |
0.804 |
|
| 1999 |
Helfenbein J, Sandell J, Halldin C, Chalon S, Emond P, Okubo Y, Chou YH, Frangin Y, Douziech L, Gareau L, Swahn CG, Besnard JC, Farde L, Guilloteau D. PET examination of three potent cocaine derivatives as specific radioligands for the serotonin transporter. Nuclear Medicine and Biology. 26: 491-9. PMID 10473187 DOI: 10.1016/S0969-8051(99)00004-9 |
0.796 |
|
| 1999 |
Zimmer L, Durand G, Guilloteau D, Chalon S. n-3 polyunsaturated fatty acid deficiency and dopamine metabolism in the rat frontal cortex. Lipids. S251. PMID 10419169 DOI: 10.1007/Bf02562309 |
0.311 |
|
| 1999 |
Chalon S, Emond P, Bodard S, Vilar MP, Thiercelin C, Besnard JC, Guilloteau D. Time course of changes in striatal dopamine transporters and D2 receptors with specific iodinated markers in a rat model of Parkinson's disease. Synapse (New York, N.Y.). 31: 134-9. PMID 10024010 DOI: 10.1002/(Sici)1098-2396(199902)31:2<134::Aid-Syn6>3.0.Co;2-V |
0.397 |
|
| 1999 |
Baulieu JL, Ribeiro MJ, Levilion-Prunier C, Tranquart F, Chartier JR, Guilloteau D, Cottier JP, Besnard JC, Pourcelot L, Autret A. Effects of the method of drawing regions of interest on the differential diagnosis of extrapyramidal syndromes using 123I-iodolisuride SPET. Nuclear Medicine Communications. 20: 77-84. PMID 9949416 DOI: 10.1097/00006231-199901000-00012 |
0.34 |
|
| 1999 |
Hall H, Halldin C, Guilloteau D, Chalon S, Emond P, Besnard J, Farde L, Sedvall G. Visualization of the dopamine transporter in the human brain postmortem with the new selective ligand [125I]PE2I. Neuroimage. 9: 108-16. PMID 9918732 DOI: 10.1006/Nimg.1998.0366 |
0.408 |
|
| 1999 |
Helfenbein J, Emond P, Loc'h C, Bottlaender M, Ottaviani M, Guilloteau D, Mazière B, Frangin Y, Chalon S. Synthesis of (E)-N-(3-bromoprop-2-enyl)-2β-carbomethoxy-3β-(4′-tolyl) nortropane (PE2Br) and radiolabelling of [76Br]PE2Br: a potential ligand for exploration of the dopamine transporter by PET Journal of Labelled Compounds and Radiopharmaceuticals. 42: 581-588. DOI: 10.1002/(Sici)1099-1344(199906)42:6<581::Aid-Jlcr218>3.0.Co;2-M |
0.803 |
|
| 1999 |
Helfenbein J, Emond P, Sandell J, Halldin C, Pereyre S, Frangin Y, Garreau L, Besnard J, Guilloteau D, Chalon S. Synthesis and radiolabelling of 2β-carbomethoxy-3β-(3′-iodo-4′-isopropylphenyl) nortropane as a radioligand for the exploration of the serotonin transporter by SPET Journal of Labelled Compounds and Radiopharmaceuticals. 42: 337-347. DOI: 10.1002/(Sici)1099-1344(199904)42:4<337::Aid-Jlcr194>3.0.Co;2-B |
0.762 |
|
| 1998 |
Emond P, Farde L, Chalon S, Belzung C, Mauclaire V, Chiron JP, Halldin C, Besnard JC, Guilloteau D. Toxicity, mutagenicity, and behavioral effects of beta-CIT, a ligand for dopamine transporter exploration by SPECT. Nuclear Medicine and Biology. 25: 405-9. PMID 9639303 DOI: 10.1016/S0969-8051(97)00227-8 |
0.335 |
|
| 1998 |
Guilloteau D, Emond P, Baulieu JL, Garreau L, Frangin Y, Pourcelot L, Mauclaire L, Besnard JC, Chalon S. Exploration of the dopamine transporter: in vitro and in vivo characterization of a high-affinity and high-specificity iodinated tropane derivative (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-m ethylph enyl)nortropane (PE2I). Nuclear Medicine and Biology. 25: 331-7. PMID 9639293 DOI: 10.1016/S0969-8051(97)00224-2 |
0.408 |
|
| 1998 |
Zimmer L, Hembert S, Durand G, Breton P, Guilloteau D, Besnard J-, Chalon S. Chronic n-3 polyunsaturated fatty acid diet-deficiency acts on dopamine metabolism in the rat frontal cortex: a microdialysis study. Neuroscience Letters. 240: 177-181. PMID 9502233 DOI: 10.1016/S0304-3940(97)00938-5 |
0.323 |
|
| 1998 |
Huguet F, Guerraoui A, Barrier L, Guilloteau D, Tallineau C, Chalon S. Changes in excitatory amino acid levels and tissue energy metabolites of neonate rat brain after hypoxia and hypoxia-ischemia. Neuroscience Letters. 240: 102-6. PMID 9486482 DOI: 10.1016/S0304-3940(97)00907-5 |
0.672 |
|
| 1997 |
Emond P, Garreau L, Chalon S, Boazi M, Caillet M, Bricard J, Frangin Y, Mauclaire L, Besnard JC, Guilloteau D. Synthesis and ligand binding of nortropane derivatives: N-substituted 2beta-carbomethoxy-3beta-(4'-iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2beta-carbomethoxy-3beta-(3',4'-disubstituted phenyl)nortropane. New high-affinity and selective compounds for the dopamine transporter. Journal of Medicinal Chemistry. 40: 1366-72. PMID 9135033 DOI: 10.1021/Jm960795D |
0.324 |
|
| 1997 |
Pellevoisin C, Guilloteau D, Baulieu JL, Loc'h C, Dognon AM, Mauclaire L, Saccavini JC, Besnard JC, Chalon S. Iodolisuride and iodobenzamide, two ligands for SPECT exploration of the dopaminergic D2 receptors: a comparative study. Synapse (New York, N.Y.). 24: 79-86. PMID 9046079 DOI: 10.1002/(Sici)1098-2396(199609)24:1<79::Aid-Syn8>3.0.Co;2-D |
0.358 |
|
| 1997 |
Pellevoisin C, Chalon S, Kung HF, Besnard JC, Guilloteau D. Is TISCH a suitable tracer for in vivo study of modifications of the dopamine D-1 receptor? Nuclear Medicine and Biology. 23: 75-8. PMID 9004918 DOI: 10.1016/0969-8051(95)02070-5 |
0.367 |
|
| 1997 |
Zouakia A, Guilloteau D, Zimmer L, Besnard JC, Chalon S. Evolution of dopamine receptors in the rat after neonatal hypoxia-ischemia: autoradiographic studies. Life Sciences. 60: 151-62. PMID 9000121 DOI: 10.1016/S0024-3205(96)00605-4 |
0.36 |
|
| 1996 |
Rafii H, Chalon S, Ombetta JE, Frangin Y, Pourcelot L, Besnard JC, Bodard S, Guilloteau D. An iodinated derivative of moclobemide as potential radioligand for brain MAO-A exploration. Life Sciences. 58: 1159-69. PMID 8614267 DOI: 10.1016/0024-3205(96)00074-4 |
0.355 |
|
| 1996 |
Lena I, Ombetta JE, Chalon S, Dognon AM, Baulieu JL, Frangin Y, Garreau L, Besnard JC, Guilloteau D. Iododerivative of pargyline: a potential tracer for the exploration of monoamine oxidase sites by SPECT. Nuclear Medicine and Biology. 22: 727-36. PMID 8535333 DOI: 10.1016/0969-8051(95)00019-T |
0.313 |
|
| 1995 |
Branger C, Garreau L, Dognon AM, Frangin Y, Caillet M, Ombetta-Goka JE, Chalon S, Besnard JC, Guilloteau D. Synthesis of 4'-iodo-5-methoxy-valerophenone O-(2-aminoethyl)oxime as an agent for exploration of serotoninergic transporter. Nuclear Medicine and Biology. 22: 157-64. PMID 7767308 DOI: 10.1016/0969-8051(94)00109-W |
0.635 |
|
| 1995 |
Rafii H, Chalon S, Ombetta J, Frangin Y, Garreau L, Dognon A, Lena I, Bodard S, Vilar M, Besnard J, Guilloteau D. Synthesis and characterization of [125I]N-(2-aminoethyl)-4-iodobenzamide as a selective monoamine oxidase B inhibitor. Nuclear Medicine and Biology. 22: 617-623. PMID 7581172 DOI: 10.1016/0969-8051(94)00144-9 |
0.323 |
|
| 1994 |
Zouakia A, Chalon S, Kung HF, Dognon AM, Saliba E, Besnard JC, Guilloteau D. Radioiodinated tracers for the evaluation of dopamine receptors in the neonatal rat brain after hypoxic-ischemic injury. European Journal of Nuclear Medicine. 21: 488-92. PMID 8082661 DOI: 10.1007/Bf00173033 |
0.355 |
|
| 1994 |
Delion S, Chalon S, Hérault J, Guilloteau D, Besnard J, Durand G. Chronic Dietary α-Linolenic Acid Deficiency Alters Dopaminergic and Serotoninergic Neurotransmission in Rats The Journal of Nutrition. 124: 2466-2476. DOI: 10.1093/Jn/124.12.2466 |
0.301 |
|
| 1994 |
Galinier E, Ombetta JE, Frangin Y, Mertens J, Besnard JC, Guilloteau D. Radiolabelling optimization of 5-(4-[125I]-iodophenyl)-2,3 dihydro-5-hydroxy-5H-imidazo[2,1-a]isoindole or [125I]-iodo mazindol : A potential tool for spect explorations Journal of Labelled Compounds and Radiopharmaceuticals. 34: 487-497. DOI: 10.1002/Jlcr.2580340512 |
0.765 |
|
| 1993 |
Pellevoisin C, Chalon S, Zouakia A, Dognon AM, Frangin Y, Baulieu JL, Besnard JC, Guilloteau D. Comparison of two radioiodinated ligands of dopamine D2 receptors in animal models: iodobenzamide and iodoethylspiperone. Life Sciences. 52: 1851-60. PMID 8502122 DOI: 10.1016/0024-3205(93)90005-N |
0.358 |
|
| 1993 |
Galinier E, Garreau L, Dognon A, Ombetta-Goka J, Frangin Y, Chalon S, Besnard J, Guilloteau D. Synthesis of halogenated analogs of 5-(4-chlorophenyl)-2,3-dihydro-5-hydroxy-5H-imidazo[2,1-a]-isoindole or mazindol for exploration of the dopamine transporter European Journal of Medicinal Chemistry. 28: 927-933. DOI: 10.1016/0223-5234(93)90047-I |
0.774 |
|
| 1992 |
Huguet F, Chalon S, Guilloteau D, Besnard JC. Spiperone: a receptor ligand and/or a granular uptake tracer? International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology. 18: 901. PMID 1800465 DOI: 10.1016/0883-2897(91)90099-7 |
0.339 |
|
| 1992 |
Foulon C, Garreau L, Chalon S, Desplanches G, Frangin Y, Besnard JC, Baulieu JL, Guilloteau D. Synthesis and in vitro binding properties of halogenated analogues of GBR as new dopamine uptake carrier ligands. International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology. 19: 597-600. PMID 1399689 DOI: 10.1016/0883-2897(92)90155-R |
0.397 |
|
| 1990 |
Chalon S, Guimbal C, Guilloteau D, Mayo W, Huguet F, Schmitt MH, Desplances G, Baulieu JL, Besnard JC. Iodobenzamide for in vivo exploration of central dopamine receptros: Evaluation in animal models of supersensitivity Life Sciences. 47: 729-734. PMID 2402193 DOI: 10.1016/0024-3205(90)90628-5 |
0.381 |
|
| 1990 |
Baulieu JL, Huguet F, Chalon S, Gerard P, Frangin Y, Besnard JC, Pourcelot L, Guilloteau D. [125I]MIBG uptake and release in different regions of the rat brain. International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology. 17: 511-4. PMID 2391247 DOI: 10.1016/0883-2897(90)90172-W |
0.339 |
|
| 1990 |
Chalon S, Frangin Y, Guilloteau D, Caillet M, Guimbal C, Schmitt MH, Desplanches G, Baulieu JL, Besnard JC. Iodoethylspiperone, a new potential agent for exploration of central dopamine D2 receptors: Synthesis and preliminary in vivo study International Journal of Radiation Applications and Instrumentation.. 17. DOI: 10.1016/0883-2897(90)90106-B |
0.38 |
|
| 1990 |
Frangin Y, Callet M, Chalon S, Huguet F, Foulon C, Desplanches G, Baulieu JL, Besnard J, Guilloteau D. A new method to prepare no-carrier-added iodinated spirodecanone derivatives:1 application to dopaminergic and serotoninergic ligands Journal of Labelled Compounds and Radiopharmaceuticals. 28: 1363-1373. DOI: 10.1002/Jlcr.2580281203 |
0.311 |
|
| 1989 |
Guilloteau D, Huguet F, Chalon S, Baulieu JL, Gerard P, Narcisse G, Pourcelot L, Besnard JC. MIBG and catecholamine storage in the brain: an in-vitro study. International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology. 15: 723-4. PMID 3251907 DOI: 10.1016/0883-2897(88)90069-4 |
0.317 |
|
| 1988 |
Guilloteau D, Chalon S, Baulieu JL, Huguet F, Desplanches G, Chambon C, Vilar MP, Pourcelot L, Besnard JC. Comparison of MIBG and monoamines uptake mechanisms: pharmacological animal and blood platelets studies. European Journal of Nuclear Medicine. 14: 341-4. PMID 3141186 DOI: 10.1007/Bf00254380 |
0.319 |
|
| 1986 |
Guilloteau D, Baulieu JL, Besnard JC. Medullary-thyroid-carcinoma imaging in an animal model: use of radiolabeled anticalcitonin F(ab')2 and meta-iodobenzylguanidine. European Journal of Nuclear Medicine. 11: 198-200. PMID 4076227 DOI: 10.1007/Bf00279068 |
0.307 |
|
| 1984 |
Guilloteau D, Baulieu JL, Huguet F, Viel C, Chambon C, Valat C, Baulieu F, Itti R, Pourcelot L, Narcisse G. Meta-iodobenzylguanidine adrenal medulla localization: autoradiographic and pharmacologic studies. European Journal of Nuclear Medicine. 9: 278-81. PMID 6745297 DOI: 10.1007/Bf00803250 |
0.305 |
|
| Show low-probability matches. |